Description
Isoverbascoside is a phenylethanoid glycoside that has been found in
C. trichotomum and has diverse biological activities. It scavenges 2,2-diphenyl-1-picrylhydrazyl (DPPH; ) radicals in a cell-free assay and inhibits hydrogen peroxide-induced lipid peroxidation in V79-4 cells when used at a concentration of 10 μg/ml. Isoverbascoside (7.5-30 μM) induces apoptosis and production of reactive oxygen species (ROS) in, and reduces viability of, OVCAR-3 cells. It inhibits tumor growth in an OVCAR-3 mouse xenograft model when administered at a dose of 30 mg/kg. Isoverbascoside (2.5 and 5 mg/kg) decreases brain amyloid deposition and increases exploratory behavior in rats when infused into the cerebral ventricles with amyloid-β (1-42) (Aβ42; ). It also decreases xylene-induced ear edema in mice and increases survival in a mouse model of LPS-induced endotoxic shock.
Chemical Properties
White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from Cistanche deserticola and Rehmannia glutinosa.
in vivo
Isoacteoside (25-100 mg/kg, ip, single dose) exhibits anti-inflammatory efficacy in mouse xylene-induced ear edema models, LPS (HY-D1056)-induced endotoxin shock models, and LPS (HY-D1056)-induced acute kidney injury (AKI) models[2].
Isoacteoside (30 mg/kg, ip, three times a week for 5 weeks) exhibits antitumor efficacy in mouse OVCAR-3 xenograft models[3].
Isoacteoside (2.5-5 mg/kg, icv for 15 days) exhibits neuroprotective effect against Aβ 1-42-induced neurotoxicity and cognitive impairment in SD rats models[5].
| Animal Model: | Acute kidney injury (AKI) model[2] |
| Dosage: | 25-100 mg/kg |
| Administration: | ip, single dose |
| Result: | Ameliorated LPS induced acute kidney injury. |
| Animal Model: | Mouse OVCAR-3 xenograft model[3] |
| Dosage: | 30 mg/kg |
| Administration: | ip, three times a week for 5 weeks |
| Result: | Reduced the tumor weight and volume. |
| Animal Model: | Aβ 1-42 induced neurotoxicity in Sprague-Dawley rats models[5] |
| Dosage: | 2.5-5 mg/kg |
| Administration: | icv for 15 days |
| Result: | Increased the exploratory behavior, shortened the escape latency. |
References
[1] SUNGWOOK CHAE. Antioxidant activity of isoacteoside from Clerodendron trichotomum.[J]. Journal of Toxicology and Environmental Health-Part A-Current Issues, 2005, 68 5: 389-400. DOI:
10.1080/15287390590900750[2] XILI YANG. Suppression of in vitro and in vivo human ovarian cancer growth by isoacteoside is mediated via sub-G1 cell cycle arrest, ROS generation, and modulation of AKT/PI3K/m-TOR signalling pathway.[J]. Journal of Buon, 2019, 24 1: 285-290.
[3] YOUNG-JI SHIAO. Acteoside and Isoacteoside Protect Amyloid β Peptide Induced Cytotoxicity, Cognitive Deficit and Neurochemical Disturbances In Vitro and In Vivo.[J]. International Journal of Molecular Sciences, 2017, 18 4. DOI:
10.3390/ijms18040895[4] HONGWEI GAO. Isoacteoside, a dihydroxyphenylethyl glycoside, exhibits anti-inflammatory effects through blocking toll-like receptor 4 dimerization[J]. British Journal of Pharmacology, 2017, 174 17: 2880-2896. DOI:
10.1111/bph.13912
